Novel SARS-CoV-2 inhibition properties of the anti-cancer Kang Guan Recipe herbal formula

Wei-Jan Wang1, Hsuan-Ting Tang2, Shi-Chen Ou3

  • 1Department of Biological Science and Technology, China Medical University, Taichung, Taiwan; Research Center for Cancer Biology, China Medical University, Taichung, Taiwan.

Cancer Letters
|August 28, 2024
PubMed

Insights

The novel Kang Guan Recipe (KGR) herbal formula shows strong potential to inhibit SARS-CoV-2 infection. KGR blocks viral entry by preventing spike protein and ACE2 interaction, offering a new COVID-19 preventive strategy.

Area of Science:

  • Virology
  • Immunology
  • Herbal Medicine

Background:

  • COVID-19 remains a global health challenge with ongoing breakthrough infections.
  • Herbal medicines show promise in combating viral infections, including SARS-CoV-2.
  • Interest is growing in alternative preventive strategies like dietary and herbal interventions.

Purpose of the Study:

  • To investigate the inhibitory activity of the Kang Guan Recipe (KGR) against SARS-CoV-2.
  • To explore the mechanism by which KGR affects SARS-CoV-2 infection.
  • To assess the in vivo efficacy of KGR against SARS-CoV-2 variants.

Main Methods:

  • In vitro testing of KGR against SARS-CoV-2 variants of concern (VOCs).
  • Analysis of KGR's effect on the interaction between the SARS-CoV-2 spike protein and human ACE2.
  • In vivo assessment of KGR's inhibitory effect on viral entry using serum from KGR-treated human subjects.

Main Results:

  • KGR demonstrated potent inhibition against SARS-CoV-2 infection, including multiple VOCs.
  • KGR was found to block the interaction between the viral spike protein and ACE2.
  • Serum from KGR-treated individuals showed suppressive activity against SARS-CoV-2 variants in vivo.

Conclusions:

  • The Kang Guan Recipe (KGR) exhibits significant antiviral activity against SARS-CoV-2.
  • KGR's mechanism involves blocking the spike protein-ACE2 interaction, a key step in viral entry.
  • KGR presents a promising herbal-based preventive and therapeutic option for COVID-19.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
154